TARGETED THERAPY IN THE TREATMENT OF PATIENTS METASTATIC COLORECTAL CANCER
Keywords:
chemotherapy, colorectal cancer, metastases, targeted drugsAbstract
Objective: to study the possibilities of targeted therapy in patients with metastatic colorectal cancer (CRC).
Methods: three groups of 75 CRC patients with liver metastases received standard chemotherapy regimens (CT) XELOX and FOLFOX4; in the experimental groups, the treatment regimens included targeted drugs bevacizumab and cetuximab.
Results: the addition of targeted drugs to the treatment regimens for patients with metastatic CRC significantly increased both the overall survival of patients and increased the time for the appearance of signs of disease progression. The median follow-up was 42.3 months. At the same time, the best results were shown by the treatment regimen, including preoperative CT according to the XELOX / FOLFOX4 + bevacizumab regimens, the targeted drug cetuximab showed less results.
Conclusions. In our study, the inclusion of targeted drugs in conventional CT regimens significantly improved the effectiveness of treatment in patients with metastatic CRC. At the same time, the treatment regimen that included preoperative CT with the addition of the targeted drug bevacizumab showed the best results.
References
Амосенко Ф.А., Карпов И.В., Поляков А.В., и др. Сравнение различных методов молекулярно-генетического анализа соматических мутаций в гене КRAS при колоректальном раке // Вестник РАМН. -2012. -№2. -С.35–41.
Баленков О.Ю., Юлдашева Д.Ю., Киреев Г.В., Камышов С.В. Изучение онкозаболеваемости населения г. Ташкента // Журнал теоретической и клинической медицины. -2007. -№3. –С.90-92.
Ибрагимов Ж.М., Туйджанова Х.Х., Ниёзова Ш.Х. и др. Cовременные аспекты коррекции гепатотоксичности, индуцированной противоопухолевой химиотерапией // Colloquium-journal. -2019. №18-1. –С.79-83.
Израильбекова К., Камышов С.В., Cabanillas M. Стратегические комбинации для предотвращения и преодоления резистентности к таргетной терапии в онкологии // Журнал теоретической и клинической медицины. -2020. -№3. –С.184-197.
Камышов С.В., Пулатов Д.А., Юлдашева Н.Ш. Изучение роли экстракорпоральной иммунофармакотерапии в снижении токсических эффектов химиолучевой терапии у пациентов с раком шейки матки // Евразийский онкологический журнал. -2015. –Т.7. -№4. –С.28-34.
Jauhri M., Bhatnagar A., Gupta S. et al. Targeted molecular profiling of rare genetic alterations in colorectal cancer using next-generation sequencing // Med. Oncol. -2016. –V.33. N10. –P.:106. doi: 10.1007/s12032-016-0820-2 PMID: 27568332
Karapetis C.S., Jonker D., Daneshmand M. et al. PIK3CA, BRAF, and PTEN status and benefit from cetuximab in the treatment of advanced colorectal cancer – results from NCIC CTG/AGITG CO.17 // Clin. Cancer Res. -2014. –V.20. -N3. –P.744-753.
Van Cutsem E., Cervantes A., Adam R. et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer // Annals of Oncology. -2016. –V.27. -N8. –P.1386-1422. doi: 10.1093/annonc/mdw235
